COVID-19 and diabetes: What do we know so far?

Prakash Gangadaran, Himabindu Padinjarathil, Shri Hari Subhashri Rajendran, Manasi P. Jogalekar, Chae Moon Hong, Baladhandapani Aruchamy, Uma Maheswari Rajendran, Sridharan Gurunagarajan, Anand Krishnan, Prasanna Ramani, Kavimani Subramanian

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.

Original languageEnglish
Pages (from-to)1330-1334
Number of pages5
JournalExperimental Biology and Medicine
Volume247
Issue number15
DOIs
StatePublished - Aug 2022

Keywords

  • COVID-19
  • SARS-CoV-2
  • diabetics
  • hyperglycemia
  • insulin resistance

Fingerprint

Dive into the research topics of 'COVID-19 and diabetes: What do we know so far?'. Together they form a unique fingerprint.

Cite this